RU2623122C2 - Моноклональные антитела и способы их применения - Google Patents

Моноклональные антитела и способы их применения Download PDF

Info

Publication number
RU2623122C2
RU2623122C2 RU2014120804A RU2014120804A RU2623122C2 RU 2623122 C2 RU2623122 C2 RU 2623122C2 RU 2014120804 A RU2014120804 A RU 2014120804A RU 2014120804 A RU2014120804 A RU 2014120804A RU 2623122 C2 RU2623122 C2 RU 2623122C2
Authority
RU
Russia
Prior art keywords
seq
amino acid
dog
antibody
monoclonal antibody
Prior art date
Application number
RU2014120804A
Other languages
English (en)
Russian (ru)
Other versions
RU2014120804A (ru
Inventor
Сара Рю
Брендан ЭККЕЛЬМАН
Куинн Деверо
Марк Насофф
Original Assignee
Новартис Тиргезундхайт АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Тиргезундхайт АГ filed Critical Новартис Тиргезундхайт АГ
Publication of RU2014120804A publication Critical patent/RU2014120804A/ru
Application granted granted Critical
Publication of RU2623122C2 publication Critical patent/RU2623122C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2014120804A 2011-10-26 2012-10-25 Моноклональные антитела и способы их применения RU2623122C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161551918P 2011-10-26 2011-10-26
US61/551,918 2011-10-26
US201261699300P 2012-09-11 2012-09-11
US61/699,300 2012-09-11
PCT/US2012/061782 WO2013063186A2 (en) 2011-10-26 2012-10-25 Monoclonal antibodies and methods of use

Publications (2)

Publication Number Publication Date
RU2014120804A RU2014120804A (ru) 2015-12-10
RU2623122C2 true RU2623122C2 (ru) 2017-06-22

Family

ID=48168777

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014120804A RU2623122C2 (ru) 2011-10-26 2012-10-25 Моноклональные антитела и способы их применения

Country Status (8)

Country Link
US (3) US9790280B2 (enExample)
EP (3) EP4530630A3 (enExample)
JP (1) JP6316195B2 (enExample)
AU (1) AU2012328819B2 (enExample)
BR (1) BR112014010008A2 (enExample)
CA (1) CA2853637C (enExample)
RU (1) RU2623122C2 (enExample)
WO (1) WO2013063186A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2830231C2 (ru) * 2018-10-18 2024-11-18 Эланко Юс Инк. Варианты fc-области с измененным связыванием с неонатальным fc-рецептором (fcrn) для применения в ветеринарии

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790280B2 (en) * 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
US10081681B2 (en) * 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
CA2932515C (en) 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
JP6554473B2 (ja) 2013-12-24 2019-07-31 アルゲン−エックス ビーブイビーエー ＦｃＲｎアンタゴニスト及び使用方法
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
AU2016230827B2 (en) * 2015-03-09 2021-10-28 argenx BV Methods of reducing serum levels of fc-containing agents using fcrn antagonists
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
JP7008020B2 (ja) 2015-12-18 2022-01-25 インターベット インターナショナル ベー． フェー． ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体
EP3416984B1 (en) 2016-02-18 2021-03-31 Elanco US Inc. Chimeric canine anti-cd20 antibody
BR112019021847A2 (pt) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
HUE065242T2 (hu) 2017-05-30 2024-05-28 Bristol Myers Squibb Co LAG-3-pozitív tumorok kezelése
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
KR20200096786A (ko) 2017-12-08 2020-08-13 아르제넥스 비브이비에이 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
BR112021006977A2 (pt) * 2018-10-18 2021-07-27 Kindred Biosciences, Inc. variantes fc com ligação alterada a receptor fc neonatal (fcrn) para uso veterinário
MX2021007680A (es) * 2018-12-27 2021-10-13 Kindred Biosciences Inc Variantes de igg fc para uso veterinario.
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
JP2021059499A (ja) 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
CA3163172A1 (en) 2020-01-08 2021-07-15 Peter Verheesen Methods for treating pemphigus disorders
US20230348577A1 (en) 2020-02-19 2023-11-02 Adivo Gmbh Modified fc regions
BR112022022352A2 (pt) * 2020-05-04 2023-01-10 Inhibrx Inc Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos
US20220024904A1 (en) * 2020-07-06 2022-01-27 Research Foundation Of The City University Of New York Reagent for bioconjugation via irreversible rebridging of disulfide linkages
KR20240021959A (ko) * 2021-06-17 2024-02-19 펫메딕스 리미티드 항개 cd20 항체
EP4380974A1 (en) * 2021-08-06 2024-06-12 Petmedix Ltd. Antibody fc variants
CN119630697A (zh) 2022-06-15 2025-03-14 阿根思有限公司 Ph依赖性hsa结合分子及使用方法
EP4642795A2 (en) 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2024155982A2 (en) 2023-01-20 2024-07-25 Invetx, Inc. Bispecific binding agents for use in companion animals
WO2024158001A1 (ja) 2023-01-25 2024-08-02 日本全薬工業株式会社 イヌのｂ細胞リンパ腫の治療方法
WO2025121944A1 (ko) * 2023-12-08 2025-06-12 주식회사 박셀바이오 개 cd20을 표적으로 하는 항체, 키메라 항원 수용체 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
EP2258726A1 (en) * 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP2002522511A (ja) 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
WO2000074718A1 (en) 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8165535B2 (en) 2006-06-04 2012-04-24 Samsung Electro-Mechanics Systems, methods and apparatuses for complementary metal oxide semiconductor (CMOS) antenna switches using switched resonators
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
CN100522999C (zh) 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
WO2003074567A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
US7615355B2 (en) * 2002-04-22 2009-11-10 Georgetown University Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration
WO2004035607A2 (en) 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
EP1761561B1 (en) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US20080299546A1 (en) 2004-02-10 2008-12-04 Nihon University Canine Cd20 Gene
WO2006007202A2 (en) 2004-05-28 2006-01-19 Idexx Laboratories, Inc Canine cd20 compositions
AU2005306502B2 (en) 2004-11-16 2012-11-15 Humanigen, Inc. Immunoglobulin variable region cassette exchange
CA2832111A1 (en) 2006-12-20 2008-07-03 Mmrglobal, Inc. Antibodies and methods for making and using them
GB0708002D0 (en) * 2007-04-25 2007-06-06 Univ Sheffield Antibodies
ES2784926T3 (es) 2007-12-21 2020-10-02 Novartis Ag Vector de expresión de mamífero
RU2528858C2 (ru) 2008-08-28 2014-09-20 Новартис Аг Дисплей на поверхности клеток полипептидных изоформ на основе прочитывания терминирующего кодона
US8569460B2 (en) 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
EP2413969A4 (en) * 2009-03-30 2012-09-05 Boehringer Ingelheim Int FUSION PROTEINS WITH DOG FC ELEMENTS
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
EP2496604B1 (en) * 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
BR112012022342A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
JP5911813B2 (ja) * 2010-03-04 2016-04-27 ベット・セラピューティクス・インコーポレイテッドＶｅｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Ｃｄ２０に対するモノクローナル抗体
US9790280B2 (en) * 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOBINAI K., [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].[Article in Japanese] Nihon Rinsho. 2002 Mar;60(3):468-72. TSIRIGOTIS P., et al., Monoclonal antibodies in the treatment of lymphoid malignancies.J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):267-71. Epub 2007 Sep 7. BUSKE C., et al., [Monoclonal antibody therapy for malignant lymphoma].[Article in German] Med Klin (Munich). 2005 Jan 15;100(1):14-24. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2830231C2 (ru) * 2018-10-18 2024-11-18 Эланко Юс Инк. Варианты fc-области с измененным связыванием с неонатальным fc-рецептором (fcrn) для применения в ветеринарии

Also Published As

Publication number Publication date
EP4530630A2 (en) 2025-04-02
US20170355775A1 (en) 2017-12-14
WO2013063186A3 (en) 2014-07-31
EP4530630A3 (en) 2025-06-18
JP2014532649A (ja) 2014-12-08
US11319377B2 (en) 2022-05-03
US20150125453A1 (en) 2015-05-07
EP3378489A1 (en) 2018-09-26
AU2012328819A1 (en) 2014-04-17
CA2853637A1 (en) 2013-05-02
CA2853637C (en) 2023-04-04
US9790280B2 (en) 2017-10-17
RU2014120804A (ru) 2015-12-10
US20220251230A1 (en) 2022-08-11
WO2013063186A2 (en) 2013-05-02
JP6316195B2 (ja) 2018-04-25
BR112014010008A2 (pt) 2018-09-04
AU2012328819B2 (en) 2017-08-03
EP2771694A2 (en) 2014-09-03
EP2771694A4 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
US20220251230A1 (en) Monoclonal antibodies and methods of use
CN109152798B (zh) 特异于糖基化的pd-1的抗体及其使用方法
KR102536017B1 (ko) 고급 당화 최종 산물(age)에 대한 항체를 사용하여 암을 치료하고, 전이성 암 세포를 사멸시키고, 암 전이를 예방하기 위한 방법 및 조성물
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
US20040265930A1 (en) Monoclonal antibody 7H11 reactive with human cancer
KR20150013935A (ko) 트랜스포터에 대한 항체 및 이의 용도
JP2010537625A (ja) ゲルゾリン結合剤組成物およびその使用
CA2753621A1 (en) Antibodies and epitopes specific to misfolded prion protein
TW201942135A (zh) 抗cd27 抗體、其抗原結合片段及其醫藥用途
JP2021531825A (ja) 葉酸受容体アルファに特異的な抗体
WO2020228604A1 (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
US7560095B2 (en) Cancer specific monoclonal antibodies
EP4070816A1 (en) Anti-gdf15 antibody
US20240262899A1 (en) Anti-cith3 antibodies and uses thereof
TWI889920B (zh) 抗ｔｒｏｐ-２抗體、其抗原結合片段或其突變體、及其醫藥用途
KR101856904B1 (ko) Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도
TW202515914A (zh) 與ｎｋｇ２ａ結合的抗體或抗原結合片段及其用途
TW201400501A (zh) 新穎抗體及其用途
EP4536713A1 (en) Monoclonal antibodies targeting conformation-specific epitopes of immunoglobulin light chains of the lambda subclass
CN116867807A (zh) Siglec-15结合蛋白的制备及其用途
EA046745B1 (ru) Способ лечения рака активируемым антителом против pdl1
NZ626513B2 (en) Anti-cd98 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner